X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
The net proceeds will fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine), an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 20, 2023
Details:
The net proceeds will fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine), an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
RP5063 (brilaroxazine) is selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
RP5063 (brilaroxazine, a topical liposomal-gel formulation) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
Brilaroxazine (RP5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
The Canadian patent covers the compositions of novel RP1208, phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, and related co-morbid conditions and depression and related co-morbid conditions.
Lead Product(s): RP1208
Therapeutic Area: Psychiatry/Psychology Product Name: RP1208
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
